Curative Biotechnology Inc (OTCMKTS:CUBT) Stock Moves Up after Latest News
Development-stage biomedical company focusing on novel therapies for rare conditions and diseases, Curative Biotechnology Inc (OTCMKTS:CUBT), announced that the registration process has commenced for creating a subsidiary in Japan. The official incorporation is expected to be August 1, 2023, which will facilitate licensing transactions as well as asset licensing in the country.
Trading Data
On Tuesday, CUBT stock moved up 21.74% to $0.0140 with more than 503.73K shares, compared to volume of 0 shares. The stock moved within a range of $0.0111 – 0.0143 after opening trade at $0.0120.
Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions
Establishment of the subsidiary is a vital milestone for the company as it looks to expand its presence and reach in the Japanese market. The new entity, Curative Biotech Japan K.K, will be located at 2-23-12 Shimomeguro Meguro ku, Tokyo 153-0064 Japan.
The firm appointed Paul Michaels as Co-CEO, even as he will continue to be the Chairman of the Board of Directors and the President. He will serve alongside I Richard Garr, Esq. as Co-CEO.
Once operational, the subsidiary will select a business executive and a seasoned pharmaceutical professional to assume the role of Representative Director. Further, Paul Michaels, Chairman of the Board of the firm’s US organization, is now the CEO of Curative Japan.
Paul Michaels, Co-CEO of Curative Biotech said that the company is excited about establishing a presence in Japan through the subsidiary. Michaels added that the strategic move enables the firm to leverage expertise and increase work within the Japanese market. He further said that the company is hoping it can contribute to ameliorating healthcare outcomes in Japan. Michaels also stated that Curative Biotech is committed to developing therapies addressing critical unmet medical needs.
